Baudax Bio Announces Pricing of $5 Million Public Offering

Written by Customer Service on December 2, 2022. Posted in Public Companies.

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share (or pre-funded warrant) and accompanying warrants. The Series A-3 warrants will have an exercise price of $4.50 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series A-4 warrants will have an exercise price of $4.50 per share, will be...

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

Written by Customer Service on December 2, 2022. Posted in Public Companies.

Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company has ranked No. 4 on the Boston Globe’s 2022 Top Places to Work in the “Large Companies” category, marking its fourth consecutive year as an honoree. The Boston Globe’s Top Places to Work, which will be featured in the print edition of Sunday’s paper, recognizes the most admired workplaces in the state, voted on by the people who know them best – their employees. The survey measures employee opinions about their company’s leadership, appreciation, benefits and more. The winners are divided into four categories...

Quality Carriers Named a Top Company for Women in Transportation

Written by Customer Service on December 2, 2022. Posted in Public Companies.

Bulk Chemicals Trucking Company Celebrated for Creating Inclusive Culture for Women Quality Carriers Named Top Company by Women in Trucking Quality Carriers staff receives 2022 Top Company for Women to Work For in Transportation Award from Women in Trucking TAMPA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) — Quality Carriers, Inc., a privately-held global logistics and transportation provider with market-leading business has been named a 2022 Top Company for Women to Work For in Transportation by Women in Trucking. “We’re very proud of this accomplishment,” said Randy Strutz, President of Quality Carriers. “Women form an integral part of our team. Whether it’s our drivers, our mechanics, or our leadership, having women in trucking is a core part of our values and a core part of our company.” Quality Carriers, a subsidiary of CSX Corporation...

Publication of Shareholder Circular

Written by Customer Service on December 2, 2022. Posted in Public Companies.

Thames Ventures VCT 1 plc (“The Company”)LEI: 213800R88MRC4Y3OIW86Publication of Shareholder Circular2 December 2022 The Company announces that it published a circular to shareholders including a Notice of a General Meeting (the “Circular“), on 2 December 2022, seeking approval to cancel the Company’s share premium account and capital redemption reserve. The Notice of the General Meeting, contained in the Circular, convenes a General Meeting to be held at 3:15 p.m. on 5 January 2023 at the offices of Foresight Group LLP, The Shard, 32 London Bridge St, London SE1. The only business of the General Meeting is to consider and, if thought fit, pass a Special Resolution in respect of the cancellation of the share premium account and capital redemption reserve. The Circular will be available shortly on the Investment Adviser’s website...

Valdor Enters Into Binding Letter of Intent With 1000175307 Ontario Ltd. for Merger Transaction

Written by Customer Service on December 2, 2022. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) — Valdor Technology International Inc. (“Valdor” or the “Company”) (CSE: VTI) is pleased to announce that it has entered into a binding letter of intent (the “LOI”) dated December 1, 2022 with 1000175307 Ontario Ltd. (“1000175307”) which contemplates the acquisition by Valdor of all of the issued and outstanding common shares of 1000175307 (the “Transaction”) from the shareholders of 1000175307. 1000175307 is party to a letter of intent that contemplates a transaction pursuant to which 1000175307 may have the option to acquire a 90% interest in and to mining rights located in South America. As consideration under the Transaction, Valdor will issue an aggregate of 72,000,000 common shares in the capital of Valdor (the “Consideration Shares”) at a deemed price of $0.10 per...

Correction: KOREA FAIR TRADE COMMISSION (KFTC) – APPEAL PROCEEDINGS UPDATE

Written by Customer Service on December 2, 2022. Posted in Dividend Reports And Estimates.

KOREA FAIR TRADE COMMISSION (KFTC) – APPEAL PROCEEDINGS UPDATE Paris – December 2, 2022. By a decision dated December 1, 2022, the Seoul High Court partially granted GTT’s appeal against the Korea Fair Trade Commission’s corrective order by revoking the €9.5 million administrative fine paid by GTT early 2021. In the same decision, the Seoul High Court confirmed the Company’s obligation to separate the technology license agreement from the technical assistance if requested by the Korean shipyards. The Company is currently reviewing the details of this decision in order to define the most appropriate available actions to best preserve its rights. GTT strongly believes that its unique expertise is key to the safe development of LNG maritime transport by providing ever more innovative, safe and efficient technologies, for...

KOREA FAIR TRADE COMMISSION (KFTC) – APPEAL PROCEEDINGS UPDATE

Written by Customer Service on December 2, 2022. Posted in Dividend Reports And Estimates.

Ålandsbanken Abp: Acquisitions of own shares 02.12.2022

Written by Customer Service on December 2, 2022. Posted in Public Companies.

Ålandsbanken Abp: Acquisitions of own shares 02.12.2022 Date 02.12.2022 ExchangeBourse trade Nasdaq Helsinki Oy (XHEL)Buy Share class ALBBV Amount 440 Average price/share 37.1000 EUR Highest price/share 37.1000 EUR Lowest price/share 37.1000 EUR Total price 16,324.00 EUR The shares held by Ålandsbanken Abp on 02.12.2022: ALBBV 268,177 On behalf of Ålandsbanken Abp Skandinaviska Enskilda Banken AB (Publ) Antti Salakka Janne Tiihonen For more information, please contact: Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505 Attachment ALBBV SBB 02122022

Innofactor Plc: Share Repurchase 2.12.2022

Written by Customer Service on December 2, 2022. Posted in Public Companies.

Innofactor Plc Announcement 2.12.2022 Innofactor Plc: Share Repurchase 2.12.2022 In the Helsinki Stock Exchange Trade date 2.12.2022 Bourse trade Buy Share IFA1V Amount 8,400 Shares Average price/ share 1.0460 EUR Total cost 8,786.40 EUR Innofactor Plc now holds a total of 1 115 045 shares including the shares repurchased on 2.12.2022 On behalf of Innofactor Plc Nordea Bank Oyj Janne Sarvikivi Sami Huttunen Additional information: Sami Ensio, CEO Innofactor Plc Tel. +358 50 584 2029 sami.ensio@innofactor.com www.innofactor.com Attachment Innofactor_2.12_trades

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Written by Customer Service on December 2, 2022. Posted in Public Companies.

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK. Details for the presentation are as follows: Poster No: P-220Title: Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjectsPresenter: Lisanne C.A. Smidt – Centre for Human Drug Research, Leiden, the NetherlandsSession: Poster Session 2Date...

Day: December 2, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice